Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PT-106** is an investigational rectal suppository developed by ProbioTech for radiation-induced proctitis. It combines a live biotherapeutic product with antioxidants and is intended to locally modulate the rectal mucosal microbiome, restore microbial balance, and mitigate oxidative injury associated with radiation exposure. The program is IND-enabling, with FDA feedback on the clinical plan pending. ([probiotechusa.com](https://probiotechusa.com/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PT-106.